MorphoSys AG : MorphoSys Signs Global License Agreement with GlaxoSmithKline
for Anti-Inflammatory Program MOR103
MorphoSys AG / MorphoSys Signs Global License Agreement with GlaxoSmithKline
for Anti-Inflammatory Program MOR103 . Processed and transmitted by Thomson
Reuters ONE. The issuer is solely responsible for the content of this
MorphoSys to Receive Committed and Success-based Payments of up to EUR445
Million and Double-digit Royalties on Net Sales
Conference call today at 5:00pm CET (4:00pm GMT/11:00am EST
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that
they have entered into a global agreement with GlaxoSmithKline (GSK) to
develop and commercialize MOR103. MOR103 is MorphoSys's proprietary
HuCAL-derived antibody against GM-CSF, which has concluded Phase 1/2
development in mild to moderate rheumatoid arthritis.
Under the terms of the agreement, GSK will assume responsibility for all
subsequent development and commercialization of MOR103. As part of the
agreement, MorphoSys receives an immediate upfront payment of EUR 22.5
million. On achievement of certain developmental, regulatory, commercial and
sales-based milestones, MorphoSys would be eligible to receive additional
payments from GSK of up to EUR423 million, in addition to tiered,
double-digit royalties on net sales.
"This transaction is a major milestone for MorphoSys. Our goal was to secure
an agreement with a company having the commitment and expertise to turn MOR103
into a successful drug, and in GSK we have clearly found such a partner. We
hope this alliance will result in a significant return on investment for the
MOR103 program and to become a major value driver for MorphoSys," commented
Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
"Today's announcement clearly illustrates our ability to take proprietary
programs from target to clinical proof of concept and an attractive
partnership. The pre-clinical and clinical data we have generated show that
MOR103 has the potential to offer new treatment options for rheumatoid
arthritis. We also believe that this molecule has potential in other
indications as well. I'm delighted that with this agreement, MOR103 will
progress to the next stage in its development," commented Dr. Arndt
Schottelius, Chief Development Officer of MorphoSys AG.
MOR103 has concluded a Phase 1 study in healthy volunteers and a Phase 1/2
clinical trial in mild to moderate rheumatoid arthritis patients.
Additionally, MOR103 is currently being evaluated in a Phase 1b
dose-escalation safety study in multiple sclerosis. MOR103 is an
investigational medicine that is not approved for use anywhere in the world.
As a result of the transaction, MorphoSys increased its financial guidance for
2013. MorphoSys expects revenues of approximately EUR 68 million to EUR 72
million (previously EUR 48 million to EUR 52 million) and an EBIT of EUR -2
million to EUR +2 million (previously EUR -18 million to EUR -22 million). The
original guidance did not include a successful out-licensing of any of the
Company's proprietary development programs. Around EUR 20 million of the
upfront payment of EUR22.5 million shall be booked with signature. The
remaining amount shall be distributed over 2013 and 2014 according to the
development plan for the ongoing phase 1b MS trial of MOR103.
MorphoSys will hold a public conference call today, 3 June 2013 at 05:00 p.m.
CEST (11:00 a.m. EDT, 04:00p.m. BST) to present more information on the
Dial-in number for the Conference Call (listen-only):
Germany: +49 89 2444 32975
For U.K. residents: +44 20 3003 2666
For U.S. residents: +1 202 204 1514
Please dial in 10 minutes before the beginning of the conference.
A webcast replay and transcript will be made available at
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys
is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates about MorphoSys, visit http://www.morphosys.com
HuCAL^®, HuCAL GOLD^®, HuCAL PLATINUM^®, CysDisplay^®, RapMAT^®, arYla^® and
Ylanthia^® and 100 billion high potentials^® are registered trademarks of
Slonomics^® is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
Media Release (PDF)
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
--- End of Message ---
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press spacebar to pause and continue. Press esc to stop.